Senior Counsel Ryan Parsons was quoted in a Law360 article, “Bold New Bench: How Trump’s Judges Are Changing The Law,” about how President Trump’s judicial appointees are transforming the federal courts for a generation or more.
Parsons said he tailored his argument in a recent appeal of his client’s pension case to the judicial philosophy of two members of the three-judge panel that heard the case – both recent Trump appointees who have demonstrated a penchant for “textualism,” a method of judicial interpretation in which judges look primarily to the precise wording of a disputed statute or contract over other factors. “I knew that those judges would be receptive to that argument,” he said.
Parsons said he tailored his argument in a recent appeal of his client’s pension case to the judicial philosophy of two members of the three-judge panel that heard the case – both recent Trump appointees who have demonstrated a penchant for “textualism,” a method of judicial interpretation in which judges look primarily to the precise wording of a disputed statute or contract over other factors. “I knew that those judges would be receptive to that argument,” he said.
Related News
25 July 2024
In the News
Donald Schroeder on Groff – ‘Supreme Court decision is inviting a more fact-based analysis’
Foley & Lardner LLP partner Donald Schroeder assessed the impact of the U.S. Supreme Court’s 2023 decision in a religious accommodation case as it returns to the district court in the Law360 article, “A Year After High Court Spotlight, Groff Case Still A Bellwether.”
24 July 2024
In the News
Louis Lehot Featured in Q&A on How Startups Can Prepare for IPO
Foley & Lardner LLP partner Louis Lehot features in the Q&A, "How startups can get in top shape for an IPO, according to Silicon Valley lawyer Louis Lehot," part of Business Insider's Road to IPO' series.
24 July 2024
In the News
Courtenay Brinckerhoff on Patent Cap in Drug Pricing – ‘Hard to predict if this will make a difference’
Foley & Lardner LLP partner Courtenay Brinckerhoff discussed a recent bill passed in the U.S. Senate aimed at lowering drug prices by limiting the number of patents that can be asserted in cases over biosimilars in the Law360 article, “Patent Cap In Drug Pricing Bill Seen As Having Muted Effect.”